In a global late-stage trial testing gefurulimab for generalized myasthenia gravis (gMG), the injection treatment candidate was shown to safely and effectively ease gMG symptoms — per both patient-reported and physician-rated scales. That’s according to the final results from this Phase 3 clinical trial, called PREVAIL (NCT05556096),…
News
Different forms of myasthenia gravis (MG) may have distinct patterns of immune system activity, with MG that appears before age 50 and MG driven by antibodies against the muscle-specific kinase (MuSK) protein showing stronger activity, a study found. “These findings underscore the immunological [variability] of MG and suggest that…
Long-term rituximab treatment safely and effectively eased symptoms and reduced the need for anti-inflammatory corticosteroids in adults with hard-to-treat generalized myasthenia gravis (gMG), according to a small, real-world study in Italy. The benefits were seen in patients with the two most common gMG-driving self-reactive antibodies, but were greater…
Adding Imaavy (nipocalimab-aahu) to standard treatment reduces hospital days by as much as 68% and lowers estimated annual hospital costs by $11,000 to $13,000 per patient for adults with generalized myasthenia gravis (gMG). That’s according to a post hoc analysis of data from the global Phase 3…
Argenx is advancing a clinical trial evaluating whether adding the experimental therapy empasiprubart to Vyvgart (efgartigimod alfa-fcab) can improve disease control in people with generalized myasthenia gravis (gMG) whose symptoms are only partly controlled with Vyvgart alone. The Phase 2a clinical trial, called ADAPT-Forward 1 (NCT07284420), is…
Kyverna Therapeutics and ElevateBio have signed a manufacturing and supply agreement for mivocabtagene autoleucel (miv-cel), Kyverna’s experimental CAR T-cell therapy for people with generalized myasthenia gravis (gMG). The new agreement covers both U.S. commercial and global clinical supply of miv-cel, formerly known as KYV-101, which is currently…
The Muscular Dystrophy Association (MDA) brought its Engage Community Seminar to Hershey, Pennsylvania, on July 18, uniting individuals with neuromuscular diseases, caregivers, and medical experts for a day of education and connection. Hosted in collaboration with the Penn State Health Milton S. Hershey Medical Center, the one-day event featured a…
Early treatment with a single low dose of rituximab rapidly eases symptoms and reduces use of corticosteroids in people with generalized myasthenia gravis (gMG) and antibodies against the acetylcholine receptor (AChR) protein, a small real-world study shows. Most of the 17 patients in the study improved within three months…
Among people with generalized myasthenia gravis (gMG) who undergo surgical removal of a thymus gland tumor, use of the approved infusion therapy Vyvgart (efgartigimod) — both before and after surgery — may help stabilize disease activity and reduce the risk of the condition worsening. That’s according to data…
Living with generalized myasthenia gravis (gMG) can make day-to-day life feel uncertain. Plans are dictated by energy levels, muscle strength, how it feels to breathe or swallow, vision problems, and how those symptoms change over the course of a day.1,2 A task that feels manageable in the morning might feel…
Recent Posts
- Guest Voice: My MG diagnosis led me to become a patient researcher
- Not asking anymore why I developed myasthenia gravis
- Global trial validates self-administered treatment for myasthenia gravis
- Reflecting on decades of rich history that led to our modern MG treatments
- Immune system activity varies across MG subtypes, study finds